Merck & Co. highlights Keytruda momentum, pharma stock in long-term focus

Merck & Co., Inc. leans on its oncology flagship Keytruda as investors watch upcoming quarterly numbers and a busy late-stage pipeline, with the pharma stock remaining in focus on the NYSE.

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-29, 07:02.

Merck & Co., Inc. (US58933Y1055) continues to draw investor attention as a large U.S. pharma player with a strong oncology franchise and a deep pipeline. The New Jersey-based group is listed on the NYSE, where it is a component of the S&P 500 healthcare segment and a widely held blue-chip stock among institutional investors.

Keytruda drives recent fundamentals

Merck & Co., Inc. has increasingly centered its growth story on the cancer drug Keytruda, which has become one of the world's best-selling prescription medicines by annual revenue in recent years as reported in company filings and sector coverage. A recent Merck investor update highlighted double-digit sales growth for Keytruda in the latest reported quarter, reflecting broader adoption in lung cancer and other indications.

In the first quarter of 2026, Merck reported that oncology revenue led its pharmaceutical business performance, with Keytruda and other cancer therapies supporting total company sales growth compared with the prior-year period according to the firm's earnings materials. Merck operates alongside major peers such as Pfizer and Bristol Myers Squibb in global oncology markets, where indications, reimbursement decisions and competitive launches can materially influence long-term sales trajectories.

Pipeline and patent considerations for long-term holders

Beyond currently marketed products, Merck & Co., Inc. is investing heavily in research and development, with a pipeline that includes immuno-oncology combinations and cardiovascular candidates at various trial stages as noted in recent R&D presentations. Keytruda itself faces patent expiry in the early 2030s in core markets, which has prompted Merck management to emphasize diversification into new mechanisms of action and additional therapeutic areas.

Merck's strategic messaging to shareholders in recent investor presentations underscores a focus on sustainable long-term growth rather than short-term earnings optimization. The company has highlighted its efforts to build on Keytruda's success via life-cycle management, including label expansions and new combination regimens, while also allocating capital to earlier-stage assets and external licensing deals that could soften eventual patent cliffs.

What Merck & Co. sells today

Merck & Co., Inc. generates the bulk of its revenue from prescription medicines, notably the oncology therapy Keytruda, as well as vaccines and hospital acute care products. Keytruda, used to treat several forms of cancer including lung and melanoma, has become a central pillar of Merck's revenue base and a key driver of its global pharmaceutical business.

Where Merck & Co. stock trades

Merck & Co., Inc. stock trades on the NYSE under the ticker MRK in U.S. dollars. As a large-cap pharmaceutical constituent of the S&P 500, the shares remain a core holding for many global healthcare investors.